Drug Trial Radar · NCT07728097
A Study to Investigate the Effect of Gradual Titration to Optimize Cannabidiol Treatment in Adults With LGS
Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
40
Planned (sponsor's estimate)
Start
Nov 18, 2026
Primary completion
Dec 28, 2028
Study completion Dec 28, 2028
Sponsor
- Lead sponsor
- Jazz PharmaceuticalsJazz Pharmaceuticals (JAZZ)
- Sponsor type
- Industry
- Collaborators
- Jazz Pharmaceuticals Research UK Limited
- First posted
- Jul 27, 2026
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 3b/Phase 4 study. The purpose of this study is to learn more about the efficacy of using CBD-OS as an add-on therapy for the treatment of LGS in adults.
Conditions
- Lennox-Gastaut Syndrome
Interventions
Cannabidiol Oral SolutionDrug
100 mg/ml Cannabidiol Oral solution (CBD-OS)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of participants reporting 50% or more reduction in their 28-day average countable major motor seizure frequencyTime frame: End of Treatment Period, Week 24
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Neuro Pain Research Center
Fresno, California
Louisiana State University Health Sciences Center New Orleans
New Orleans, Louisiana
Velocity Clinical Research At Raleigh Neurology
Raleigh, North Carolina
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.